查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984208

非侵入性液態生物檢體市場：按技術、生物標記、檢體類型、應用和最終用戶分類－2026-2032年全球市場預測

Non-Invasive Liquid Biopsy Market by Technology, Biomarker, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，非侵入性液態生物檢體市場價值將達到 52.8 億美元，到 2026 年將成長至 57.7 億美元，到 2032 年將達到 98.4 億美元，年複合成長率為 9.29%。

主要市場統計數據
基準年 2025 52.8億美元
預計年份：2026年 57.7億美元
預測年份 2032 98.4億美元
複合年成長率 (%) 9.29%

本文全面說明了非侵入性、以液體為基礎的分子診斷如何過渡到主流臨床工作流程和精準醫療範式。

非侵入性液態生物檢體正迅速從小眾研究工具發展成為基礎臨床診斷方法，革新了生物訊號的收集、解讀和應用方式。核酸檢測、先進定序和高靈敏度數位定量技術的創新推動了這一發展，使臨床醫生和研究人員能夠從周邊血液和其他體液中獲取可操作的分子資訊。因此，傳統的切片檢查正逐漸被基於體液的檢測方法所取代，後者俱有降低患者風險、可重複採樣以及早期療育的潛力等優點。

本報告從多方面檢驗了技術進步、監管變革和經營模式的融合，這些融合正在重新定義非侵入性診斷和臨床應用的途徑。

非侵入性液態生物檢體領域正經歷著一場變革性的轉變，這場轉變是由技術、監管和臨床動態的融合所驅動的，它全面重塑了檢測、解讀和後續治療的路徑。首先，次世代定序化學、誤差抑制技術和數位定量技術的進步，顯著提升了分析能力，擴大了可偵測訊號的範圍，從而能夠更早發現疾病並更可靠地監測微量殘存疾病。這些技術進步與生物資訊學的成熟相輔相成，機器學習驅動的變異檢測和多成分融合方法提高了特異性並降低了假陽性率。

對計劃於 2025 年進行的美國關稅調整將如何影響整個診斷生態系統的供應鏈、籌資策略和製造地進行策略分析。

美國宣布將於2025年調整關稅，其累積影響正造成商業性和營運方面的複雜性，相關人員必須積極應對。影響診斷設備、定序耗材和特殊試劑的關稅措施可能會改變平台提供者和檢查室網路的接收成本。為此，製造商正努力修訂籌資策略、最佳化材料清單(BOM) 並審查關稅分類，以在維持供應鏈連續性的同時，最大限度地減少成本波動。

透過對多維細分進行全面整合，揭示技術、應用、生物標記和最終用戶方面的差異如何影響產品的適用性和臨床應用。

細分市場分析揭示了技術選擇、臨床應用、生物標記標靶和終端用戶群體如何共同決定液態生物檢體解決方案的價值提案和應用路徑。技術細分區分了數位PCR平台（包括各種束流式和液滴式數位PCR）與涵蓋標靶定序、全EXOME序和全基因組定序的次世代定序方法。同時，定量PCR仍然是成熟檢測方法的常用選擇。每種技術系列在靈敏度、通量和成本結構方面各有側重，了解這些權衡對於使檢測設計與臨床目標相符至關重要。

從地理平衡的觀點解釋區域法規結構、償還環境和基礎設施成熟度如何決定全球市場商業化的軌跡。

區域趨勢對策略至關重要，因為獨特的管理體制、報銷系統和醫療基礎設施決定了它們如何影響液態生物檢體解決方案的推廣。在美洲，整合的醫療體系和私人實驗室網路能夠實現快速的臨床檢驗和廣泛的保險談判，這往往推動了臨床創新，而官民合作關係進一步推進了人群篩檢試點計畫和腫瘤治療路徑。在歐洲、中東和非洲，監管協調工作和國家醫療技術評估流程呈現出碎片化的特點，需要量身定做的證據包和區域性的商業策略。集中化的監理合作和區域採購機制也常常影響市場進入的順序。

一份精闢的競爭分析報告，揭示了垂直整合、夥伴關係框架和技術差異化如何推動產業內企業的策略定位。

對主要企業的分析表明，策略定位、能力整合和夥伴關係關係是決定競爭優勢的主要因素。成熟的儀器製造商通常會利用其現有的儀器基礎設施和服務網路來加速新檢測方法的推廣應用，而定序平台提供者則在通量、誤差控制和生態系統支援（例如文庫構建試劑盒和雲端分析）方面競爭。診斷試劑盒和試劑供應商專注於其供應鏈中可靠且可重複的生產流程，而專業的生物資訊公司則透過專有的變異檢測技術、多樣檢體融合演算法以及簡化終端用戶解讀的臨床報告工作流程來脫穎而出。

一系列可操作的、優先排序的策略建議，旨在幫助產業領導者協調技術開發、證據生成和商業性實施，以實現永續成長。

針對行業領導者的實際建議著重於使產品開發與臨床需求保持一致，增強供應鏈韌性，並優先創建能夠引起保險公司和指南制定機構共鳴的證據。製造商應逐步投資於模組化設計，以便在關稅和物流挑戰出現時能夠輕鬆進行組件替換和在地採購，從而在短期供應和長期平台擴充性之間取得平衡。同時，企業需要投資於全面的臨床檢驗項目，以證明產品在早期檢測和微量殘存疾病（MRD）等目標適應症中具有顯著的臨床效用，並設計能夠反映常規臨床工作流程的可操作性臨床試驗。

我們透明且可重複的研究框架，結合了與關鍵相關人員的互動、同行評審證據的整合以及情境分析，從而得出可靠的策略結論。

本調查方法整合了多方面的證據收集、嚴格的檢驗和迭代整合，以確保研究結果既反映技術現狀，也反映臨床實踐。主要資料輸入結合了檢查室管理人員、臨床研究人員和行業高管的結構化訪談，以及對同行評審的臨床研究、監管申報文件和會議報告的分析，從而全面檢驗檢測方法的性能和臨床效用。次要研究則透過梳理技術進步、供應鏈結構和區域法規結構，補充並闡釋這些研究結果的策略意義。

一項具有前瞻性的綜合分析，將技術成熟度、證據要求和營運策略與透過液態生物檢體創新可實現的臨床影響聯繫起來。

總之，非侵入液態生物檢體正處於一個轉折點，技術成熟、證據累積和經營模式不斷演進在此交匯，創造了巨大的臨床機會。隨著檢測靈敏度和分析能力的提升，曾經的設想正逐步轉化為現實的臨床應用，尤其是在腫瘤學、感染疾病監測和產前篩檢。然而，成功需要技術開發人員、檢查室營運者、保險公司和監管機構之間的密切合作，以確保產生充分的證據、明確臨床工作流程並實現經濟高效的實施。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 非侵入性液態生物檢體市場：依技術分類

  • 數位PCR
    • BEAMing
    • 液滴式數位PCR
  • 次世代定序
    • 目標序列
    • 全EXOME定序
    • 全基因組定序
  • 定量PCR

第9章 生物標記分類的非侵入性液態生物檢體市場

  • 細胞中的遊離DNA
  • 循環腫瘤DNA
  • 外泌體

第10章檢體類型分類的非侵入性液態生物檢體市場

  • 航班
  • 尿
  • 唾液

第11章 非侵入性液態生物檢體市場：按應用領域分類

  • 癌症篩檢
    • 早期檢測
    • 微量殘存疾病的監測
  • 感染疾病診斷
  • 產前檢查
    • 染色體異常篩檢
    • 單基因疾病篩檢

第12章 非侵入性液態生物檢體市場：依最終用戶分類

  • 私人考試機構
  • 醫院檢查室
  • 研究機構

第13章 非侵入性液態生物檢體市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 非侵入性液態生物檢體市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 非侵入性液態生物檢體市場：按國家/地區分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國非侵入性液態生物檢體市場

第17章：中國無創液態生物檢體市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Angle PLC
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Biocept, Inc.
  • DiaCarta, Inc.
  • Epic Sciences Inc.
  • F. Hoffmann-La Roche Ltd.
  • Grail, Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Integrated DNA Technologies, Inc.
  • Laboratory Corporation of America Holdings
  • Lonza Group Ltd.
  • Lucence Diagnostics Pte. Ltd.
  • LungLife AI, Inc.
  • Mdxhealth BV
  • MedGenome Labs Ltd.
  • Menarini Silicon Biosystems SpA
  • Merck KGaA
  • Natera, Inc.
  • Nonacus Limited
  • Norgen Biotek Corporation
  • Oasis Diagnostics Corporation
  • OraSure Technologies, Inc
  • QIAGEN GmbH
  • Thermo Fisher Scientific Inc.
  • Zymo Research Corp.
Product Code: MRR-5C6F41F5B02E

The Non-Invasive Liquid Biopsy Market was valued at USD 5.28 billion in 2025 and is projected to grow to USD 5.77 billion in 2026, with a CAGR of 9.29%, reaching USD 9.84 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.28 billion
Estimated Year [2026] USD 5.77 billion
Forecast Year [2032] USD 9.84 billion
CAGR (%) 9.29%

An integrated overview explaining how non-invasive fluid-based molecular diagnostics are transitioning into mainstream clinical workflows and precision medicine paradigms

Non-invasive liquid biopsy is rapidly evolving from a niche research tool into a foundational clinical diagnostic approach that reshapes how biological signals are captured, interpreted, and applied. This evolution is driven by innovations in nucleic acid detection, advanced sequencing, and sensitive digital quantitation, which together enable clinicians and researchers to obtain actionable molecular information from peripheral blood and other bodily fluids. As a result, the traditional reliance on tissue biopsies is progressively complemented by fluid-based assays that offer reduced patient risk, repeatable sampling over time, and the potential for earlier intervention.

In practice, liquid biopsy workflows intersect laboratory science, bioinformatics, and clinical decision-making. Diagnostic sensitivity improvements and biomarker discovery have broadened clinical utility beyond oncology into infectious disease surveillance and prenatal screening, thereby increasing cross-disciplinary adoption. Moreover, the integration of robust informatics pipelines has converted raw assay signals into clinically meaningful outputs, accelerating translational pathways and fostering payer conversations.

Consequently, stakeholders across healthcare-platform developers, clinical laboratories, hospital systems, payers, and regulators-face a collective imperative to adapt governance, reimbursement frameworks, and operational models. As such, this introduction frames liquid biopsy not merely as an incremental diagnostic advancement but as a systemic enabler of precision medicine that requires coordinated investment in technology, evidence generation, and ecosystem alignment.

A nuanced examination of converging technological gains, regulatory shifts, and commercial models that are redefining non-invasive diagnostics and clinical adoption pathways

The landscape of non-invasive liquid biopsy is undergoing transformative shifts driven by converging technological, regulatory, and clinical dynamics that collectively redefine detection, interpretation, and downstream care pathways. First, analytic performance gains- propelled by improvements in next-generation sequencing chemistry, error suppression methods, and digital quantitation-have expanded detectable signal windows, enabling earlier disease detection and more reliable minimal residual disease monitoring. These technical advances are complemented by bioinformatics maturation, where machine learning-enhanced variant calling and multi-analyte fusion approaches increase specificity and reduce false positives.

At the same time, clinical adoption curves are being reshaped by accumulating real-world evidence and consensus guideline updates that validate certain liquid biopsy applications. Payers are increasingly receptive when clinical utility is demonstrated through prospective studies and cost-effectiveness analyses, which in turn incentivizes wider clinical uptake. Meanwhile, commercial strategies are shifting from single-assay propositions toward platform-centric offerings that bundle hardware, consumables, and analytics into subscription or service models, thereby lowering entry barriers for end users.

Finally, supply chain resilience and global partnerships are influencing strategic decisions; manufacturers are diversifying sourcing and pursuing regional manufacturing footholds to mitigate geopolitical and logistic risks. Consequently, the market is morphing from an early-adopter phase into an operationally complex, clinically driven ecosystem where sustained differentiation will depend on demonstrable clinical impact, scalable operations, and integrated payer engagement.

A strategic analysis of how United States tariff adjustments planned for 2025 are reshaping supply chains, procurement strategies, and manufacturing footprints across the diagnostics ecosystem

The cumulative impact of United States tariff adjustments announced for 2025 introduces a layer of commercial and operational complexity that stakeholders must proactively manage. Tariff measures affecting diagnostic instrumentation, sequencing consumables, and specialized reagents can change landed costs for platform providers and laboratory networks. In response, manufacturers are recalibrating procurement strategies, optimizing bill-of-materials, and engaging in tariff classification reviews to minimize cost disruption while maintaining supply chain continuity.

Beyond immediate price effects, tariffs influence strategic location decisions; some firms accelerate investments in regional manufacturing or assembly to qualify for preferential trade treatment and reduce exposure to cross-border duty burdens. This shift often produces near-term capital expenditure and long-term resilience benefits, but it can also increase unit costs and complicate production planning. Importantly, clinical laboratories and hospital systems that depend on imported equipment may experience compressed gross margins unless manufacturers or distributors absorb or offset tariff-driven increases.

Moreover, tariffs can catalyze innovation in materials science and assay design, prompting efforts to substitute high-duty components with domestically sourced or lower-duty alternatives. Regulatory engagement becomes essential in such transitions, as modifications to hardware or reagent formulations may necessitate device revalidation and dialogue with oversight bodies. In the context of collaborative research and international partnerships, tariff uncertainty reinforces the value of diversified supplier networks and adaptive contracting that incorporate duty-sharing clauses and inventory buffers to sustain uninterrupted clinical services and research continuity.

A comprehensive synthesis of multi-dimensional segmentation revealing how technology, application, biomarker, and end-user distinctions shape product fit and clinical adoption

Segmentation insights reveal how technology choices, clinical applications, biomarker targets, and end-user configurations collectively determine value propositions and adoption pathways for liquid biopsy solutions. Technology segmentation distinguishes digital PCR platforms, which include BEAMing and droplet-based digital PCR variants, from next-generation sequencing approaches that encompass targeted sequencing, whole exome sequencing, and whole genome sequencing, while quantitative PCR remains an accessible option for established assays. Each technological family delivers a distinct balance of sensitivity, throughput, and cost structure, and understanding these trade-offs is critical to matching assay design with clinical intent.

Application segmentation underscores the breadth of clinical use cases, with cancer screening expanding beyond symptomatic diagnosis to include early detection and minimal residual disease monitoring, while infectious disease diagnostics and prenatal testing serve complementary clinical domains; within prenatal testing, approaches address both chromosomal abnormality screening and single gene disorder screening. These application-driven requirements dictate assay sensitivity thresholds, turnaround time expectations, and evidence-generation strategies.

Biomarker segmentation highlights cell-free DNA as a versatile analyte, with circulating tumor DNA representing a disease-specific subset used extensively in oncology, and exosomes offering a rich source of proteomic and nucleic acid signals that may enhance biological resolution. Lastly, end-user segmentation shows diverse operational contexts across commercial laboratories, hospital laboratories, and research institutes, each with distinct procurement models, throughput needs, regulatory pressures, and integration capabilities. Taken together, these intersecting segmentation dimensions guide product roadmaps, reimbursement engagement, and clinical validation strategies.

A geographically informed perspective that explains how regional regulatory frameworks, reimbursement landscapes, and infrastructure maturity determine commercialization trajectories across world markets

Regional dynamics are critical to strategy, with distinct regulatory regimes, reimbursement systems, and healthcare infrastructure influencing how liquid biopsy solutions scale. In the Americas, clinical innovation is often driven by integrated healthcare systems and commercial laboratory networks that enable rapid clinical validation and broad insurance negotiations, while private and public partnerships further advance population screening pilots and oncology care pathways. Europe, the Middle East & Africa present a mosaic of regulatory harmonization efforts and national health technology assessment processes that require tailored evidence packages and localized commercial strategies; centralized regulatory cooperation and regional procurement mechanisms often influence market entry sequencing.

Across Asia-Pacific, diverse healthcare markets range from highly developed precision medicine ecosystems with advanced sequencing adoption to emerging markets where cost-effective, scalable screening solutions are prioritized. Regional manufacturing capacity, digital infrastructure maturity, and local policy incentives for biotechnology investment also shape where companies choose to invest in clinical trials, supply networks, and commercial teams. In all regions, cross-border collaborations and data-sharing frameworks increasingly underpin multicenter studies, enabling comparability and facilitating broader guideline incorporation. Therefore, regional strategies must balance global platform coherence with localized execution to capture clinical and commercial opportunities effectively.

An incisive review of competitive dynamics showing how vertical integration, partnership architectures, and technological differentiation are driving strategic positioning across industry players

Key company insights emphasize strategic positioning, capability integration, and partnership orchestration as primary determinants of competitive advantage. Established instrument manufacturers often leverage installed bases and service networks to accelerate adoption of new assays, whereas sequencing platform providers compete on throughput, error suppression, and ecosystem support such as library kits and cloud-based analytics. Diagnostic kit and reagent suppliers focus on supply-chain reliability and reproducible manufacturing processes, while specialized bioinformatics firms differentiate through proprietary variant calling, multi-analyte fusion algorithms, and clinical reporting workflows that streamline interpretation for end users.

At the same time, innovative start-ups are pursuing narrow clinical niches or integrated service models that combine sample collection, high-sensitivity assays, and longitudinal reporting to address specific clinical gaps such as recurrence monitoring or population-level screening. Collaboration patterns increasingly involve co-development agreements between technology vendors and clinical laboratory networks to accelerate clinical validation and reimbursement dialogues. Consequently, vertical integration-spanning assay chemistry, instrumentation, software, and laboratory services-emerges as a recurring strategic theme, as does the use of strategic equity partnerships and licensing arrangements to expand geographic reach and reduce time-to-market.

Practical and prioritized strategic recommendations designed to help industry leaders align technology development, evidence generation, and commercial execution for sustainable growth

Actionable recommendations for industry leaders focus on aligning product development with clinical need, strengthening supply chain resilience, and prioritizing evidence generation that resonates with payers and guideline bodies. Manufacturers should sequence investments to balance near-term access with long-term platform scalability, adopting modular designs that facilitate component substitution and localization when tariffs or logistics create headwinds. Simultaneously, companies must invest in comprehensive clinical validation programs that demonstrate meaningful clinical utility for targeted indications such as early detection and minimal residual disease, while designing pragmatic trials that reflect routine clinical workflows.

On the commercial side, stakeholders should pursue flexible go-to-market models that combine direct laboratory services, partnerships with hospital systems, and channel distribution to reach different end users. Investment in interoperable analytics and clear clinical reporting standards will lower barriers for adoption among clinicians. Additionally, proactive engagement with payers and health technology assessment agencies to co-develop real-world evidence strategies will accelerate reimbursement discussions. Finally, industry leaders should cultivate collaborative ecosystems-linking technology providers, laboratories, and academic centers-to share data, harmonize standards, and expedite translation from assay innovation to scalable clinical practice.

A transparent and reproducible research framework combining primary stakeholder engagement, peer-reviewed evidence synthesis, and scenario analysis to support robust strategic conclusions

The research methodology integrates multi-source evidence collection, rigorous validation, and iterative synthesis to ensure findings reflect both technological realities and clinical practice. Primary data inputs include structured interviews with laboratory directors, clinical investigators, and industry executives, combined with analysis of peer-reviewed clinical studies, regulatory filings, and conference disclosures to triangulate assay performance and clinical utility. Secondary research complements these insights by mapping technology trajectories, supply-chain configurations, and regional regulatory frameworks to contextualize strategic implications.

Analytical processes involve cross-validation of technical claims against independent performance studies, sensitivity analyses of supply-chain scenarios, and scenario planning to assess the potential effects of policy changes such as tariffs or reimbursement shifts. Throughout, methodological transparency is maintained by documenting inclusion criteria for studies and interview protocols, thereby enabling reproducibility and critical appraisal. Finally, iterative expert review cycles were used to surface divergent perspectives and reconcile them into coherent, actionable conclusions that support decision-making for stakeholders across the diagnostics ecosystem.

A forward-looking synthesis that connects technical maturity, evidence requirements, and operational strategy to the achievable clinical impact of liquid biopsy innovations

In conclusion, non-invasive liquid biopsy stands at an inflection point where technical maturity, evidence accumulation, and evolving commercial models converge to create substantial clinical opportunity. As assay sensitivity and informatics capabilities improve, applications that once seemed speculative are transitioning into realistic clinical pathways, particularly for oncology, infectious disease surveillance, and prenatal screening. Nevertheless, success will require deliberate alignment among technology developers, laboratory operators, payers, and regulators to generate the appropriate evidence, define clinical workflows, and ensure cost-effective deployment.

Moreover, external factors such as trade policy adjustments and regional infrastructure variation will influence operational choices and investment priorities. Organizations that adopt adaptive supply-chain strategies, pursue modular and validated platform designs, and prioritize stakeholder collaboration are most likely to convert technical advantage into durable clinical impact. Ultimately, the ability to translate analytical performance into actionable clinical decisions will determine which solutions achieve broad adoption and drive the next phase of precision diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-Invasive Liquid Biopsy Market, by Technology

  • 8.1. Digital PCR
    • 8.1.1. BEAMing
    • 8.1.2. Droplet Digital PCR
  • 8.2. Next Generation Sequencing
    • 8.2.1. Targeted Sequencing
    • 8.2.2. Whole Exome Sequencing
    • 8.2.3. Whole Genome Sequencing
  • 8.3. Quantitative PCR

9. Non-Invasive Liquid Biopsy Market, by Biomarker

  • 9.1. Cell Free DNA
  • 9.2. Circulating Tumor DNA
  • 9.3. Exosomes

10. Non-Invasive Liquid Biopsy Market, by Sample Type

  • 10.1. Stool
  • 10.2. Urine
  • 10.3. Saliva

11. Non-Invasive Liquid Biopsy Market, by Application

  • 11.1. Cancer Screening
    • 11.1.1. Early Detection
    • 11.1.2. Minimal Residual Disease Monitoring
  • 11.2. Infectious Disease Diagnostics
  • 11.3. Prenatal Testing
    • 11.3.1. Chromosomal Abnormality Screening
    • 11.3.2. Single Gene Disorder Screening

12. Non-Invasive Liquid Biopsy Market, by End User

  • 12.1. Commercial Laboratories
  • 12.2. Hospital Laboratories
  • 12.3. Research Institutes

13. Non-Invasive Liquid Biopsy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Non-Invasive Liquid Biopsy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Non-Invasive Liquid Biopsy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Non-Invasive Liquid Biopsy Market

17. China Non-Invasive Liquid Biopsy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Angle PLC
  • 18.6. Bio-Rad Laboratories, Inc.
  • 18.7. Bio-Techne Corporation
  • 18.8. Biocept, Inc.
  • 18.9. DiaCarta, Inc.
  • 18.10. Epic Sciences Inc.
  • 18.11. F. Hoffmann-La Roche Ltd.
  • 18.12. Grail, Inc.
  • 18.13. Guardant Health, Inc.
  • 18.14. Illumina, Inc.
  • 18.15. Integrated DNA Technologies, Inc.
  • 18.16. Laboratory Corporation of America Holdings
  • 18.17. Lonza Group Ltd.
  • 18.18. Lucence Diagnostics Pte. Ltd.
  • 18.19. LungLife AI, Inc.
  • 18.20. Mdxhealth BV
  • 18.21. MedGenome Labs Ltd.
  • 18.22. Menarini Silicon Biosystems SpA
  • 18.23. Merck KGaA
  • 18.24. Natera, Inc.
  • 18.25. Nonacus Limited
  • 18.26. Norgen Biotek Corporation
  • 18.27. Oasis Diagnostics Corporation
  • 18.28. OraSure Technologies, Inc
  • 18.29. QIAGEN GmbH
  • 18.30. Thermo Fisher Scientific Inc.
  • 18.31. Zymo Research Corp.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DROPLET DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CELL FREE DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CELL FREE DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CELL FREE DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STOOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STOOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY STOOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY MINIMAL RESIDUAL DISEASE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CHROMOSOMAL ABNORMALITY SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CHROMOSOMAL ABNORMALITY SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CHROMOSOMAL ABNORMALITY SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SINGLE GENE DISORDER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SINGLE GENE DISORDER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SINGLE GENE DISORDER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COMMERCIAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 178. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 179. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 180. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 183. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 184. GCC NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 208. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 209. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 210. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 213. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 214. G7 NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 218. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 219. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 220. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 223. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 224. NATO NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY DIGITAL PCR, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY BIOMARKER, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY CANCER SCREENING, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY PRENATAL TESTING, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA NON-INVASIVE LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)